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Olivia A. Lambourne,[a] and Youcef Mehellou*[a]  
PINK1 is a ubiquitously expressed mitochondrial 
serine/threonine protein kinase that has emerged as a key 
player in mitochondrial quality control. This protein kinase 
came to prominence in mid-2000s, when PINK1 mutations 
were found to be causative of early-onset Parkinson’s 
disease (PD). As most of these PD-related mutations 
occurred in the kinase domain and impaired PINK1 catalytic 
activity, it was suggested that small molecules that activate 
PINK1 would maintain mitochondrial quality control and as a 
result offer advantageous neuroprotective effects. Working 
on this hypothesis, few small molecule PINK1 activators, 
which offered critical insights and distinct approaches for 
activating PINK1, have to date been discovered. Herein, we 
briefly highlight the discovery of these small molecules and 
offer a future insight into the development of small molecule 
PINK1 activators as potential treatments for PD.  
The discovery of PTEN-induced kinase 1 (PINK1) mutations as 
causative of early-onset PD in 2004[1] represents a landmark 
ﬁnding in the field of PD. This is because it provided the ﬁrst direct 
evidence of mitochondrial dysfunction having a primary role in the 
development of PD. PINK1 is a unique protein kinase as it has an 
N-terminal mitochondrial targeting domain and three insertion
loops within its catalytic kinase domain.[2] Back then, the 
molecular mechanism by which PINK1 mutations contributed to 
the development of PD was unclear. However, a series of 
fundamental discoveries have since been made, which provided 
a clearer understanding of how PINK1 mutations cause PD.[3]  
Interestingly, most of the PINK1 mutations identified to date, fall 
within the kinase domain and abolish its catalytic activity.[4] Indeed, 
all of the seventeen human PD PINK1 missense mutations 
studied were found to have suppressed or completely depleted 
kinase activity in vitro compared to the wild-type PINK1 kinase.[4] 
This finding indicated that restoring or maintaining PINK1 kinase 
activity could pose as a potential therapeutic strategy for PD. This 
hypothesis was supported by subsequent studies that indicated 
that the loss of PINK1 resulted in stress-induced mitochondrial 
dysfunction and neuronal apoptosis in many mammalian cells 
including neuronal cells, a phenomenon that was rescued by the 
overexpression of PINK1 wild-type.[5] Furthermore, the kinase 
activity of PINK1 was also noted in Drosophila models as being 
critical for the mitochondrial translocation of its E3 ubiquitin ligase 
substrate, parkin,[6] a key process in the eventual repair or 
removal of damaged mitochondria. 
At the molecular level, PINK1 is recruited to the mitochondria via 
its N-terminal mitochondrial targeting domain, which is then 
cleaved off allowing a truncated version of PINK1 to dissociate 
from the mitochondria. This short version of PINK1 is then rapidly 
degraded via the N-end rule pathway and ubiquitin–proteasome 
system.[7] However, in damaged mitochondria, where there is a 
loss of the mitochondrial membrane potential (Dym), PINK1 
associates with the translocase of the outer membrane (TOM) on 
the outer mitochondrial membrane (OMM) allowing it to 
homodimerize, autophosphorylate and as a result become 
catalytically active.[8] Subsequently, active PINK1 phosphorylates 
parkin, which is also mutated in early-onset PD,[9] at serine 65 
(Ser65) and ubiquitin also at Ser65.[3b, 3c, 3h, 3j] This leads to the 
activation of parkin and the ubiquitylation of a series of OMM 
proteins.[8, 10] This eventually results in the recruitment of ubiquitin 
adaptor proteins and the engulfment of the damaged 
mitochondria by autophagosomes, a process termed mitophagy, 
which recycles the damaged mitochondria (Figure 1).[3k]  
Figure 1. PINK1-signalling in healthy and damaged mitochondria. Under 
resting conditions, healthy mitochondria, PINK1 is recruited to the outer 
mitochondrial membrane (OMM) and degraded. However, when the 
mitochondria is damaged (¯¯¯ Dym), PINK1 is stabilized on the OMM 
where it phosphorylates parkin at Ser65 and ubiquitin at Ser65, a process 
that induces mitophagy and results in the recycling of damaged 
mitochondria. 
Although in vivo studies into PINK1-related mitophagy have been 
scarce, a recent report indicated the level of neuronal basal 
mitophagy in PINK1 knock out mice was comparable to the wild-
type.[11] This observation should be taken with caution as PINK1 
knockout mice do not show Parkinson-like symptoms[12] and the 
PINK/Parkin signaling pathway was not stimulated in this in vivo 
study. Nevertheless, mitophagy is still well-supported as a 
protective mechanism that avoids the toxic accumulation of 
damaged or excess mitochondria in cells and consequently 
oxidative damage and cell death.[13] Together, these discoveries 
imply that PINK1 may act as a master regulator of mitochondrial 
quality control within neurons and hence provided a direct link 
between PINK1 activity and neurodegeneration. [a] Olivia A. Lambourne and Dr. Youcef Mehellou 
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Working on the hypothesis that PINK1 activation would have 
beneficial neuroprotective effect that could slow down the 
progression of Parkinson’s disease, some attempts at discovering 
small molecule PINK1 activators have been reported as 
discussed below.  
Small molecule PINK1 activators 
To date, only few small-molecule PINK1 activators have been 
identified and these could be classified into two groups depending 
on their mechanism of action. These are direct activators, which 
are believed to act on PINK1 directly, and indirect activators, 
which do not act directly on PINK1 to produce their effects.  
1. Direct PINK1 activators
This first discovery of a direct small molecule PINK1 activator was
made by the Shokat lab in 2013 when they reported that kinetin
riboside triphosphate (KTP) acts as an ATP neo-substrate and
activates PINK1 in vitro and in cells.[14] This was a result of the
finding that kinetin riboside triphosphate with a gamma
thiophosphate (KTPgS) was used as an ATP neo-substrate by the
recombinant PINK1 WT kinase domain and its G309D mutant with
a better efficiency than the natural substrate ATP in vitro.[14]
Encouragingly, analysis of this in vitro reaction products indicated
that the PINK1 kinase domain as well as the PINK1 peptide
substrate used in this assay had a thiophosphate group
incorporated.[14] This confirmed the ability of PINK1 to use KTPgS
as a neo-substrate to autophosphorylate and also subsequently
phosphorylate its substrates.[14] Notably, a selection of other N6-
substituted adenosines triphosphates, e.g. N6-benzyl adenosine
triphosphate, were unable to activate PINK1 in vitro.[14] In cells, it
was shown that the KTP precursor kinetin underwent four
consecutive metabolic (activation) steps, one glycosylation and
three phosphorylation bioconversions, to generate the active KTP
metabolite (4, Figure 2A), which acted as a PINK1 ATP-neo-
substrate.[14] Indeed, in cells treated with kinetin, KTP was
detected and a degree of PINK1 activation was also observed as 
judged by increased phosphorylation of the anti-apoptotic protein 
Bcl-xL, a PINK1 substrate.[14] Although subsequent work showed 
that long-term oral dosing of kinetin did not protect against α-
synuclein-induced neurodegeneration in rodent models of PD,[15] 
it must be noted that kinetin itself is of very low efficacy in cells[14] 
and no studies as of yet have reported on the brain uptake of the 
nucleobase kinetin.     
To generate more potent PINK1 activators, we hypothesized that 
working at the nucleoside monophosphate level, i.e. kinetin 
riboside monophosphate (3, Figure 2), would by-pass the 
glycosylation and first phosphorylation steps, which if they do not 
proceed with high efficiency in cells and in vivo, would limit the 
amounts of active KTP generated. However, it is well established 
that nucleoside analogues monophosphates have poor cellular 
uptake. This is because of  their incompatibility with membrane 
nucleoside transporters, extracellular dephosphorylation to 
generate the parent nucleoside and their polar (negatively 
charged) nature at physiological pH (< 7.4), which limits their 
passive diffusion across cell membranes.[16] To overcome these 
challenges, a number of monophosphate prodrug approaches 
have been developed (see Hecker and Erion,[16b] Wiemer and 
Wiemer[17]) and these have been used widely in the discovery of 
nucleotide-based therapeutics.[18] Among the most successful 
monophosphate prodrug approaches is the ProTide 
technology,[19] which to date has delivered over ten clinical 
candidates and two FDA-approved drugs.[20] In this prodrug 
approach, the monophosphate group is masked by an aryl group 
and an amino acid ester generating a prodrug that is neutral at 
physiological pH and is passively taken up by cells (Figure 2B).[19] 
Upon cell entry, the masking groups are enzymatically cleaved off 
to release the nucleoside analogue monophosphate, which could 
then be further phosphorylated by cellular nucleotide kinases to 
the active triphosphate species (Figure 2B).[19] 
Figure 2. Nucleobase, nucleoside and ProTide activators of PINK1. A. Chemnical structure of kinetin and ist metabolites leading tot he genration oft he 
active PINK1 ATP-neosubstrate KTP. B. Cellular uptake and postulated metabolism of kinetin riboside ProTides. R = methyl, isopropyl, tert butyl and 
benzyl. 
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Encouraged by the success of the ProTide technology in 
discovering nucleotide-based therapeutics, we applied this 
prodrug approach to kinetin riboside monophosphate, KMP.[21] 
Four KMP ProTides were synthesized with varying esters (methyl, 
isopropyl, tertbutyl and benzyl). These were shown to be stable in 
human serum for >12 h and were metabolized in vitro by 
carboxypeptidase Y to generate the desired nucleotide metabolite. 
When studied for their ability to activate PINK1 in HEK293 cells 
stably overexpressing PINK1 and transiently transfected with 
parkin, these ProTide prodrug showed far superior activation of 
PINK1 compared to the parent nucleobase kinetin.[21] This was 
judged by parkin Ser65 phosphorylation after treatment with 
different concentrations of KMP ProTides. Interestingly, the 
nucleoside kinetin riboside was also able to activate PINK1 in 
cells to a level comparable to that observed with the most potent 
KMP ProTide.[21] This suggested that the glycosylation of kinetin 
into kinetin riboside rather than the first phosphorylation step may 
be the rate-limiting step in the four bioconversion steps of kinetin 
into its active KTP. The data from this study confirmed the initial 
observation of kinetin being a weak activator on PINK1 in cells 
and this may explain the lack of in vivo PINK1 activation using 
kinetin.[15] Additionally, it supported our hypothesis that for 
unnatural (modified) nucleobases such as kinetin, their multi-step 
bioconversion in cells and in vivo may not be as efficient as for 
natural nucleobases and this ultimately limits their 
pharmacological efficacy. Overall, this work highlighted that 
working on the nucleoside or the nucleoside monophosphate 
levels could yield more potent activators for PINK1 than the use 
of nucleobases.  
2. Indirect PINK1 activator
As mentioned above, the loss of the mitochondrial membrane
potential leads to the activation of PINK1.[3b] Inspired by this
observation, a number of compounds that are known to disrupt
mitochondrial function have been identified as promising PINK1
activators. Among these are the proton ionophores carbonyl
cyanide m-chlorophenyl hydrazone (CCCP) and carbonyl
cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) as well as
the potassium uniporter  valinomycin.[3b, 8] Interestingly, unlike
CCCP and FCCP, valinomycin was able to depolarize the
mitochondrial membrane potential without affecting the pH
gradient indicating that PINK1 is specifically activated by loss of
the mitochondrial membrane potential (Dym). Despite the
promise of these agents in activating PINK1, their cellular toxicity
has hindered their in vivo investigations and their possible
development as potential small molecule PINK1 activators. Keen
on discovering safe small molecules that could manipulate
mitochondrial membrane potential and thus activate PINK1, we
focused our attention niclosamide (Figure 3), a clinical agent that
has been reported in numerous studies to uncouple mitochondrial
membrane potential.[22] Niclosamide is an anthelminthic drug
used for decades to treat tapeworm infections[23] and it has an
encouraging safety profile in vivo.[22b, 24]
Treatment of parkin-overexpressing HeLa cells, which express
PINK1 endogenously,  with niclosamide led to potent activation of
PINK1 EC50 in cells as judged by parkin phosphorylation at Ser65.
Additionally, in niclosamide treated cells  CISD1, a substrate of
parkin,[25] was ubiquitylated in a niclosamide dose-dependent
manner indicating the activation of the PINK1 and parkin. Notably,
this PINK1 downstream signaling, namely parkin S65
phosphorylation and CISD1 ubiquitylation, was abolished in
PINK1 KO cells treated with niclosamide. In vitro kinase assays
indicated that niclosamide was not able to activate recombinant
PINK1 suggesting that niclosamide is an indirect activator of this 
kinase. This observation was supported by data from cell assays 
showing the cleavage of full length OPA1[26] protein because of 
mitochondrial membrane depolarization in wild-type as well as 
PINK1 KO cells treated with niclosamide. Given the simple 
chemical structure of niclosamide, three of its derivatives (Figure 
3) were synthesized and only one of these, AM85, showed PINK1
activation comparable to niclosamide. Encouragingly,
niclosamide and AM85 activation of PINK1 was not limited to cell
studies as it was also observed in cultured neurons.[25]
Studies into understanding how niclosamide and AM85 activated
PINK1 indicated that they both induced mitochondrial membrane
uncoupling, a phenomenon known to activate PINK1.[3b, 25]
Intriguingly, the mitochondrial membrane uncoupling effect
caused by niclosamide and AM85 was reversible and did not
cause permeant damage to the mitochondrial membrane
potential.[25]
Despite the promise of niclosamide as a PINK1 activator, it has a 
number of limitations that hinder its possible repurposing for the 
treatment of PD. First, niclosamide is a promiscuous compound 
since it manipulates many signaling pathways in cells and in 
vivo.[23] Deconvoluting the niclosamide-mediated PINK1 
activation mechanism from the other non-PINK1 related effects, 
albeit it a challenge, would be extremely informative and would 
facilitate the discovery of more specific PINK1 activators. Second, 
as a drug molecule, niclosamide has poor drug-like properties that 
include poor solubility and inefficient absorption. Thus, in many 
studies, niclosamide prodrugs with improved drug-like properties 
have been used.[22b, 27] However, to date, these niclosamide 
prodrugs have been studied in non-central nervous system 
conditions and therefore their brain-penetration properties are 
unknow.  
Future Outlook 
Given the direct genetic link between PINK1 mutations and PD, it 
is of no surprise to see an increased pursuit of the discovery of 
PINK1 activators as potential PD treatments. Although this pursuit 
is yet to deliver compounds with drug-like properties that support 
their in vivo studies, there is no doubt that the PINK1 activators 
discussed in this Highlight have confirmed the amenability of 
PINK1 to be activated by small molecules and both classes of 
PINK1 activators, direct and indirect, may have the potential to 
treat PD in the future. The immediate step from these early 
discovery studies is the optimisation of these compounds to 
generate potent, safe and brain-penetrant PINK1 activators. This 
may be a relatively easier challenge for direct PINK1 activators as 
compared to the indirect ones, whose exact molecular target is 
yet to be identified. It is also worth noting that for indirect PINK1 
activators, especially those that operate by depolarizing the 
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Figure 3. Chemical structures of niclosamide and its analogues that have 
been studied for PINK1 activation.  
mitochondrial membrane, their safety in vivo needs to be 
established prior to extensive in vivo studies and progression in 
the pre-clinical development pipeline. Ultimately, the challenge for 
PINK1 activators will be whether they exhibit PINK1 activation in 
vivo that is sufficient to induce meaningful neuroprotective effects 
and hence offer hope in treating PD. Notably, with some reports 
linking PINK1 and its mutations to sporadic PD,[28] PINK1 
activators may have a wider use in treating this disease than 
initially thought.  
Overall, the highlighted potential of small molecule PINK1 
activators as well as the remaining PINK1-related unanswered 
questions show that this field is still at its early stages and there 
is a lot more to be discovered over the next few years. Together, 
this makes the discovery of small molecule PINK1 activators 
scientifically exciting and will inform and influence the discovery 
and development of new PD therapeutics.    
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